Jeffrey Scott

Compliance Program

• Conducted compliance program assessment for a global Fortune 500 industrials company and advised on strategic improvements to increase program effectiveness
• Developed and executed on a health care and regulatory compliance program for a pre-commercial bio-tech company preparing for commercialization
• Provided advice and implementation support to a life science company's overhaul of its US speaker program policy, processes and system
• Counseled life science company on revamping its US fair market value methodology for engagement of HCPs
• Advised on development of global samples policy for multinational life sciences company and counseled on implementation and change management across multiple markets
• Led effort for multinational life science company to evaluate and update its US policies and processes for co-pay cards
• Supported launch of multinational life science company's commercial-focused, business-led global compliance committee, including development of risk registry and process for tracking and oversight of projects
• Advised on a multi-year internal process and system overhaul project of a multinational life science company's compliance department

AI, Data Analytics and Technology

• Advised on compliance program aspects of corporate ethical AI policy and program for multinational life sciences company
• Advised on development of AI facet of life science company's third-party risk program
• Provided compliance counseling and implementation support on the roll out of approved third-party messaging applications (WeChat and WhatsApp) at a global life sciences company
• Oversaw multinational life science company's compliance data analytics strategy and supported pull through of strategy, including evaluation of strategy and capabilities against the Department of Justice (DOJ) Compliance Program guidance

Investigative

• Conducted investigation related to adverse event reporting by sales organization of Japanese affiliate of multinational life science company
• Coordinated global compliance due diligence of acquisition's operations and performed on-site reviews at Indian manufacturing facilities for life science company
• Conducted investigation into life science company's US sales and marketing practices and patient interactions in support of a rare disease product
• Managed multiple investigations for life sciences company related to meals and gifts provided to healthcare professionals (HCPs) who are licensed in US states with gift or meal prohibitions
• Conducted investigation into evaluation process for adverse events by safety organization of life science company
• Overhauled company's internal investigations processes and matter manager guidelines
• Led assessment of global speaker program practices in various global markets for multi-national life sciences company
• Conducted an internal review of life science company's HCP Engagements and HCP spend in Russian market

• Panelist, "One Size Does Not Fit All: How to Design an Actionable AI and Data Analytics Blueprint That Aligns with Your Company’s Infrastructure, Resources, and Risk Profile" ACI'S Forum on AI and Data Analytics for Anti-Corruption Compliance, December 2, 2025
• Panelist, "AI Enforcement Trends in Pharma and Med Device: What is Happening Now and What to Expect in the Future?" 26th Annual Pharmaceutical Compliance Forum (PCF) Pharma Congress, October 22, 2025
• Speaker, "Ethical AI and AI Risk – Where Do I Start?" Association of Corporate Counsel (ACC) Greater Philadelphia Ethics and Compliance Continuing Legal Education (CLE), March 19, 2025
• Speaker, "The Rising Stakes of Data Governance and How Companies are Responding, Chief Compliance Officer Roundtable," 24th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress, October 25, 2023
• Speaker, "Ethics by Design: Embedding Ethics into Uses of Data and Artificial Intelligence in the Pharmaceutical Industry," Drug Information Association (DIA) Global Annual Meeting, June 28, 2023
• Speaker, "Data Ethics as a Catalyst of Trust in Pharmaceutical Innovation and Regulation," DIA Europe, March 24, 2023

Immediately before joining DLA Piper, Jeffrey worked at a Fortune 500 pharmaceutical company in their Corporate Compliance Organization in various roles with increasing seniority. In his last role, he led a team that managed digital risk (e.g. AI, third-party communication apps), oversaw systems and processes for the Compliance organization, and provided data analytics support across the Compliance function. Prior to that role, Jeffrey served as Compliance Lead for the company's Global Internal Medicine business and as Compliance Lead for the company's Strategy and Operations Organization. Earlier in his in-house career, he was part of the Compliance Investigations team where he conducted investigations in both the US and in Japan, Korea and Taiwan across a broad range of issues.

Jeffrey previously owned his own consulting practice where he focused on grass-roots political activities in support of legislation and candidates.

Earlier in his career, Jeffrey was a litigation associate at an Am Law 100 Firm in New York and an Am Law 100 Firm in Philadelphia.